Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Yale University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07118332CT.gov Psilocybin as a Treatment for Chronic Pain in Smokers | — | Not Yet Recruiting | — | — | — |
NCT06988319CT.gov Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study | — | Not Yet Recruiting | — | — | — |
NCT05585229CT.gov Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | — | Recruiting | — | — | — |
NCT06919640CT.gov Psilocybin With Intracranial Neural Sensing | — | Enrolling By Invitation | — | — | — |
NCT06518720CT.gov Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Teonanacatl (this asset) | Yale University | P2 | B · 59 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Jnj-54135419 | Beijing Tiantan Hospital | P4 | BBB |
| Buprenorphine | Medical University of South Carolina | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Teonanacatl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Depressive Disorder | — | P2 | BB · 68 |
| Major Depressive Disorder | — | P3 | BB · 65 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Teonanacatl in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/teonanacatl-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →